Search
Arrowhead Pharmaceuticals Inc
ARWRAdd to Watchlist
81.820USD
+0.780+0.96%
Close 06/18, 16:00（ET）Quotes delayed by 15 min
11.50BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-18The current earnings forecast score of Arrowhead Pharmaceuticals Inc is 8.00, ranking 165 out of 389 in the Biotechnology & Medical Research industry. The average price target is 61.00, with a high of 85.00 and a low of 17.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
88.182
Target Price
+8.81%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
560
Total
5
Median
6
Average
Company name
Ratings
Analysts
Arrowhead Pharmaceuticals Inc
ARWR
14
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
FAQs
What is Arrowhead Pharmaceuticals Inc's expected revenue for the next quarter?
Arrowhead Pharmaceuticals Inc's expected revenue is 54.90M.
What is Arrowhead Pharmaceuticals Inc's price target?
Analysts forecast that Arrowhead Pharmaceuticals Inc's price target is USD 61.00, with the highest forecast at USD 85.00 and the lowest forecast at USD 17.00.
How have Arrowhead Pharmaceuticals IncARWR's recent earnings per share performed?
The market expectation was USD -0.93, while Arrowhead Pharmaceuticals IncARWR's earnings per share (EPS) for the previous quarter was USD 0.22. EPS for the next quarter is expected at USD -1.30.
What is the analyst rating for Arrowhead Pharmaceuticals Inc?
Based on the ratings of Arrowhead Pharmaceuticals Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.
